Inhibition, STAT3, Inflammation, Phase I Clinical Trial, Europe Rock Creek Pharmaceuticals Announces Inhibition of STAT 3 Activation, A Key Marker of Inflammation, In Phase I Clinical Trial in Europe http://finance.yahoo.com/news/rock-creek-pharmaceuticals-announces-inhibition-134500908.html Feb 3, 2016